Why the study?
Does CABG added to medical therapy reduce mortality compared to medical therapy alone in patients with ischemic cardiomyopathy and LVEF ≤35% across different age groups?
Does CABG added to medical therapy reduce mortality compared to medical therapy alone in patients with ischemic cardiomyopathy and LVEF ≤35% across different age groups?
CABG added to medical therapy provides a consistent long-term benefit on cardiovascular mortality regardless of age in patients with ischemic cardiomyopathy, although the benefit on all-cause mortality is more pronounced in younger patients.
No takes yet. Share an insight, caveat, or question.
CABG benefit on CV mortality appears consistent across ages in ischemic HF; leaves open confirmation in broader nonrandomized cohorts.
Petrie et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: